Biblio Discovery — Demo Discovery Service

5 results for "Jay Overholser"

Showing 1–5 · 0.15 seconds · RSS

  1. Journal Article Full text

    Mitochondrial VDAC1: A Potential Therapeutic Target of Inflammation-Related Diseases and Clinical Opportunities

    Hang Hu; Linlin Guo; Jay Overholser et al.

    Cells, Vol. 11 No. 19 · 2022 · English · DOAJ Scopus

    The multifunctional protein, voltage-dependent anion channel 1 (VDAC1), is located on the mitochondrial outer membrane. It is a pivotal protein that maintains mitochondrial function to power cellular bioactivities via energy generation. VDAC1 is involved in regulating energy production…

  2. Journal Article

    A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx)

    Linlin Guo; Jay Overholser; Heather Darby et al.

    OncoImmunology, Vol. 11 No. 1 · 2022 · English · DOAJ Scopus

    Blockade of checkpoint receptors with monoclonal antibodies against CTLA-4, PD-1 and PD-L1 has shown great clinical success in several cancer subtypes, yielding unprecedented responses albeit a significant number of patients develop resistance and remain refractory. Both PD-1/PD-L1 and HER-2…

  3. Journal Article

    Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model

    Pravin T. P. Kaumaya; Linlin Guo; Jay Overholser et al.

    OncoImmunology, Vol. 9 No. 1 · 2020 · English · DOAJ Scopus

    Therapeutic blockade of PD-1/PD-L1 signaling with monoclonal antibodies (mAbs) has shown clinical success and activity across a broad set of cancer subtypes. However, monotherapy with PD-1/PD-L1 inhibitors are only effective in a subset of patients and ongoing studies show efficacy of treatment…

  4. Journal Article

    Preclinical Studies of a Novel Human PD-1 B-Cell Peptide Cancer Vaccine PD1-Vaxx From BALB/c Mice to Beagle Dogs and to Non-Human Primates (Cynomolgus Monkeys)

    Linlin Guo; Jay Overholser; Anthony J. Good et al.

    Frontiers in Oncology, Vol. 12 · 2022 · English · DOAJ Scopus

    Immunotherapy with monoclonal antibodies to checkpoint inhibitors against the PD-1/PD-L1 signaling pathway is a landmark achievement in cancer therapy. Some anti-PD-1 inhibitors such as nivolumab and pembrolizumab have shown clinical success, in a percentage of patients with prolonged survival…

  5. Journal Article Full text

    Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC)

    Jay Overholser; Kristen Henkins Ambegaokar; Siobhan M. Eze et al.

    Vaccines, Vol. 3 No. 3 · 2015 · English · DOAJ Scopus

    Despite the promise of targeted therapies, there remains an urgent need for effective treatment for esophageal cancer (EC) and triple-negative breast cancer (TNBC). Current FDA-approved drugs have significant problems of toxicity, safety, selectivity, efficacy and development of resistance. In this…